Andrés Cervantes

55PUBLICATIONS
368CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (55)

|Aug 13, 2026
Worldwide Innovative Network Consortium: Building a Common Global Cancer Database.

|Jun 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

|May 04, 2026
Spatial Dynamics Links PD-L1 and Tumor-Associated Macrophage-Enriched Niches to Immune and Mesenchymal States in Microsatellite-Stable Colorectal Cancer.

|Apr 14, 2026
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.

Devalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro

|Apr 14, 2026
Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy.

Mar Iglesias Coma, Jordi Badia-Ramentol, Carolina Martinez-Ciarpaglini

|Nov 18, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.

Ignacio Melero, Josep Tabernero, Neeltje Steeghs

Pageof 10

Frequent Collaborators

7 joint publications

Marisol Huerta

6 joint publications

Susana Roselló

6 joint publications

Valentina Gambardella

5 joint publications

Josep Tabernero